StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
CLBTBearishLegalnews
High materiality7/10

Kaplan Fox Investigation Pressures CLBT After ARR Miss and CEO Change

Aug 13, 2026, 6:51 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The combination of a formal or potential securities investigation with a quarterly ARR miss and abrupt CEO change typically compounds downside risk, fueling investor concern about governance, disclosures, and future cash flows. Historical context shows such headlines often lead to volatility and multiple compression until clarity is provided.

AI summary

What happened, with direct paths to the underlying reporting

Cellebrite faces near-term pressure as Q2 ARR misses guidance and a leadership change coincides with a securities investigation. ARR came in at $507.8M, below the $510-513M range, prompting a midpoint ~$15M guidance cut. The abrupt CEO shift to Shiv Ramji adds governance questions while legal scrutiny introduces heightened investor risk.

  • Q2 ARR: $507.8M; misses guidance of $510-513M.
  • Full-year ARR guidance cut by midpoint about $15M; delays cited.
  • CEO Tom Hogan out; Shiv Ramji named new CEO effective immediately.
  • Cellebrite stock down 29% to $10.80 on Aug 13, 2026.
  • Kaplan Fox launches securities investigation into CLBT.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event